Study Summary
The goal of this prospective, multicentric, single-arm, phase I/II clinical trial is to evaluate the safety and efficacy of a novel CD19-directed CAR-T cell locally produced in an academic institution in Brazil in patients with refractory or relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants will receive a single intravenous infusion of an autologous academic anti-CD19 CAR-T cell and will be followed for 5 years.
Want to learn more about this trial?
Request More InfoInterventions
CART-19BIOLOGICAL
The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hospital de Clínicas da UNICAMP | Campinas | São Paulo | Brazil |
| Ribeirao Preto School of Medicine, University of Sao Paulo | Ribeirão Preto | São Paulo | Brazil |
| Hospital Sírio-Libanês | São Paulo | São Paulo | Brazil |
| Hospital das Clinicas de São Paulo | São Paulo | São Paulo | Brazil |
| A Beneficência Portuguesa de São Paulo | São Paulo | São Paulo | Brazil |